or Try an Advanced Search...

    Technical Analysis for AMRN - Amarin Corporation plc

    Grade Last Price % Change Price Change
    F 0.87 1.72% 0.01
    AMRN closed up 1.72 percent on Friday, April 26, 2024, on 31 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 1
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical AMRN trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Outside Day Range Expansion 1.72%
    Wide Bands Range Expansion 1.72%
    Oversold Stochastic Weakness 1.72%
    Stochastic Buy Signal Bullish -0.42%
    NR7 Range Contraction -0.42%
    Older End-of-Day Signals for AMRN ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 16 hours ago
    Possible Inside Day about 16 hours ago
    Up 2% about 21 hours ago
    Up 1% about 21 hours ago
    60 Minute Opening Range Breakdown 2 days ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    AMRN Chart by TradingView
    Basic chart:

    Profile

    Amarin Corporation plc Description

    Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases. Its product development program areas include lipid science and therapeutic benefits of polyunsaturated fatty acids. The company lead product comprises Vascepa, a prescription-only omega-3 fatty acid comprising icosapent ethyl as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It also engages in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is headquartered in Dublin, Ireland.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Acid Organic Compounds Cardiovascular Disease Therapeutic Products Vascular Disease Lipid Nutrition Cholesterol Lipoprotein Fatty Acids Low Density Lipoprotein Triglyceride Hypertriglyceridemia Statin Therapy

    Is AMRN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 24 Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
    Apr 22 Amarin Announces Results of Annual General Meeting of Shareholders
    Apr 16 Amarin Corporation: Small Signs Of Recovery May Not Be Enough
    Apr 15 Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
    Apr 8 Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
    Apr 8 New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
    Apr 6 New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
    Apr 4 Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe
    Apr 3 Why Amarin Stock Was Rocketing Higher on Wednesday
    Apr 3 Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
    See more AMRN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.485
    52 Week Low 0.651
    Average Volume 1,573,038
    200-Day Moving Average 0.97
    50-Day Moving Average 0.98
    20-Day Moving Average 0.95
    10-Day Moving Average 0.88
    Average True Range 0.05
    RSI (14) 41.18
    ADX 21.33
    +DI 14.44
    -DI 22.89
    Chandelier Exit (Long, 3 ATRs) 0.95
    Chandelier Exit (Short, 3 ATRs) 1.01
    Upper Bollinger Bands 1.11
    Lower Bollinger Band 0.79
    Percent B (%b) 0.26
    BandWidth 33.87
    MACD Line -0.03
    MACD Signal Line -0.02
    MACD Histogram -0.0076
    Fundamentals Value
    Market Cap 357.21 Million
    Num Shares 408 Million
    EPS -0.12
    Price-to-Earnings (P/E) Ratio -7.29
    Price-to-Sales 1.54
    Price-to-Book 0.89
    PEG Ratio -1.74
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.90
    Resistance 3 (R3) 0.90 0.89 0.90
    Resistance 2 (R2) 0.89 0.88 0.89 0.90
    Resistance 1 (R1) 0.88 0.88 0.89 0.88 0.90
    Pivot Point 0.87 0.87 0.87 0.87 0.87
    Support 1 (S1) 0.86 0.86 0.87 0.87 0.85
    Support 2 (S2) 0.85 0.86 0.85 0.85
    Support 3 (S3) 0.84 0.85 0.85
    Support 4 (S4) 0.85